1. Epidemiological significance of bufexamac as a frequent and relevant contact sensitizer;Kränke;Contact Dermatitis,1997
2. Bufexamac is a frequent contact sensitizer;Kränke;Contact Dermatitis,1996
3. European Medicines Agency European Medicines Agency recommends revocation of marketing authorisations for bufexamac http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/04/WC500089623.pdf
4. European Medicines Agency Questions and answers on the revocation of the marketing authorisations for medicines containing bufexamac http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Bufexamac_107/WC500089665.pdf
5. Allergy to tea tree oil: retrospective review of 41 cases with positive patch tests over 4.5 years;Rutherford;Australas. J. Dermatol.,2007